Iovance Biotherapeutics Inc (IOVA) Gets a Buy Rating from Chardan Capital


Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Iovance Biotherapeutics Inc (IOVA) today and set a price target of $20. The company’s shares opened today at $9.80.

According to TipRanks.com, Livshits is a 1-star analyst with an average return of -0.6% and a 75.0% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Intellia Therapeutics, and Editas Medicine Inc.

Currently, the analyst consensus on Iovance Biotherapeutics Inc is a Strong Buy with an average price target of $25, implying a 155.1% upside from current levels. In a report issued on March 19, Oppenheimer also reiterated a Buy rating on the stock.

See today’s analyst top recommended stocks >>

Based on Iovance Biotherapeutics Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $32.58 million. In comparison, last year the company had a GAAP net loss of $26.52 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Iovance Biotherapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients’ tumors.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts